Cannabis is currently the world's foremost illicit substance consumed -the United Nations estimates that it is used by 3.9% of the world's adult population. 2 Co-morbid substance abuse is a confirmed risk factor for poorer symptomatic and functional outcomes in individuals with mental illness. 3, 4 Furthermore, service costs for individuals with, for example, a dual diagnosis of schizophrenia and substance abuse, can be twice that for patients without such diagnoses. 5 The rate of co-morbid cannabis consumption in individuals with schizophrenia is reportedly high. In their review of 53 clinical studies, Green et al. found that the lifetime prevalence of cannabis use was 42.2%, and of cannabis misuse, 22.5%. 6 A number of correlates and risk factors predicting substance use in schizophrenia populations have emerged with some consistency.
These include being unmarried, being male, and having lower educational levels, a childhood conduct disorder or a co-morbid antisocial personality disorder. 3, [7] [8] [9] Although research on the effects of cannabis abuse on clinical parameters in individuals with schizophrenia has produced conflicting results, two prospective studies attempting to examine the longer-term outcome of cannabis use in this illness have both demonstrated poorer outcome and increased intensity of positive symptoms. 10, 11 A number of prospective epidemiological studies also now provide support for the hypothesis that cannabis abuse increases the subsequent risk for developing schizophrenia. [12] [13] [14] In South Africa, the exact prevalence of cannabis use/abuse among the general population, as well as among individuals with mental disorders, has not been formally studied, but it is generally believed to be high. 16 Another study looking at risk factors for violence in a schizophrenic inpatient population,
showed lifetime cannabis abuse to be 33% in the violent sample, and 27% in the non-violent sample. 17 In view of the paucity of existing data, the purpose of this study was therefore to try to identify the demographic and clinical correlates of cannabis abuse in a large South African schizophrenia group. To limit confounding factors, a decision was made to use an ethnically homogeneous population. Interviews were supplemented by hospital/clinic chart records and collateral information from family members, where available.
Methods
Patients were also questioned on their use of substances of abuse, and a urinary drug screen was performed on all participants.
Use/abuse of cannabis was defined as using cannabis more than 21 times in a single year, based on the DIGS criteria. 
Results

Demographic variables
The original study recruited 547 participants, of whom 52 were were male and 32.8% (N=82) were female. The gender distribution difference between the two groups was statistically significant (p<0.0001). Table I shows additional demographic variables. 
Illness variables
Clinical variables
Statistically significant differences between the two groups could be documented for all of the positive symptom subscores as recorded on the SAPS. With reference to negative symptom subscores as recorded on the SANS, the only difference reported was that for the avolition/apathy subscale, with significantly higher scores for the CUA group (p<0.0001). Table IV presents full clinical variables.
Discussion
The overall lifetime prevalence of cannabis use/abuse in our study was 49.49%, which was comparable to the mean 42.2% As demonstrated previously in the literature, our study group also showed a lower mean age of onset of illness in the cannabis use/ abuse group. 7 Three possible mechanisms have been suggested in the literature to explain this finding: Firstly, it is possible that cannabis has no influence on risk or age at onset, and that younger patients, compared with older patients, are more likely to use this substance before the first psychotic episode because its use is also age-related. 21 Secondly, cannabis use could hasten the onset of psychosis in individuals who would have developed this disorder even if they had never used the substance; this notion is supported by evidence suggesting that cannabis may trigger or exacerbate psychotic symptoms in healthy individuals and schizophrenic patients. 22 A third suggested mechanism is that cannabis lowers the threshold for developing schizophrenia in those genetically at risk for developing it. It is known that the 
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Both nicotine and alcohol use/abuse were common in our entire sample, but there were almost twice the number of nicotine users, and three times the number of alcohol abusers, in the cannabis use/abuse group. Overall, there was a 22.4% lifetime prevalence of alcohol abuse in the total sample of 547, which is almost twice the 11.4% lifetime prevalence rate of alcohol abuse recently reported for the general South African population. 24 Very few other substances of abuse were reported in our sample, which is similar to findings of other previously reported South
African schizophrenia samples. 17, 25 The absence of methamphetamine use/abuse in our sample, in view of the current high prevalence rates of methamphetamine use/abuse in the Western Cape, is notable. Secondly, cannabis has for generations been regarded as a traditional drug among the indigenous southern African populations, and its use has therefore possibly been associated with low moral blameworthiness. 27 Thirdly, the relatively higher articles 29 It is known that deficiencies of this pathway may cause movement disorders.
Possible limitations of this study included the following: (i) assessment instruments were not translated into Xhosa; (ii) the assessment relied on historical information with possible recall bias; and (iii) the group sample was mixed with regard to hospitalisation status and, therefore, stage of illness.
Strengths of this study included the use of (i) a large, ethnically homogeneous population; (ii) validated structured clinical interviews; and (iii) multiple sources of information.
Conclusion
The prevalence of cannabis use/abuse in our study population was found to be significant and comparable with previous international studies. Cannabis use/abuse started mainly in the teenage years, was more prevalent among males and was found to have a negative association with outcome, in terms of the degree of symptomatology as well as rates of hospitalisations and relapses. The prevalence of co-morbid alcohol and nicotine abuse was also found to have a positive correlation with cannabis use/abuse. Taken together, our findings underscore the clear need for a targeted dual diagnosis service to improve outcomes for our clients. Finally, our study results also seem to suggest that the practice of urine cannabis testing appears to add little value in routine management of known schizophrenic patients. A thorough interview with reliable collateral information would seem to be sufficient to exclude substance abuse in the majority of such cases.
